Is it appropriate to initiate benazepril therapy in a patient with hypertension who has no known cardiac or hepatic disease?

Yes, benazepril is appropriate to initiate in this patient with hypertension who has no known cardiac or hepatic disease.

Benazepril, an ACE inhibitor, is explicitly recommended as a first-line antihypertensive agent for patients with hypertension and is safe to use in the absence of contraindications. 1, 2

Rationale for Use

The most recent 2024 ESC guidelines clearly state that ACE inhibitors (including benazepril) are among the first-line treatments recommended for lowering blood pressure, having demonstrated the most effective reduction in BP and cardiovascular events 1. The FDA label confirms benazepril is indicated for hypertension treatment to reduce fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions 2.

Key Safety Considerations

Your patient has NO contraindications to benazepril based on the information provided:

• Absolute contraindications (which your patient does NOT have): pregnancy, history of angioedema, renovascular disease 3, 2
• Cautions (which your patient does NOT have): renal impairment, peripheral vascular disease 3

The absence of known heart disease or liver disease actually makes this patient an ideal candidate for ACE inhibitor therapy, as there are no organ-specific concerns that would require dose adjustment or alternative therapy.

Clinical Evidence Supporting Use

The ACCOMPLISH trial demonstrated that benazepril-based combination therapy effectively reduces cardiovascular events in high-risk hypertensive patients 4, 5, 6. In patients without compelling indications for other agents, benazepril has shown:

• Effective BP reduction of approximately 15 mmHg systolic and 10 mmHg diastolic 7
• Excellent tolerability with adverse event rates similar to placebo 8, 9
• 73.6% effectiveness at 3 months, increasing to 84.7% at 18 months 10

Practical Implementation

Starting approach:

• Begin with benazepril 10 mg once daily (standard starting dose) 2
• Can be taken at any convenient time of day to improve adherence 1
• Monitor BP within 2-4 weeks and titrate to 20-40 mg daily if needed 2

Monitoring requirements:

• Baseline: serum creatinine, potassium, blood pressure
• Follow-up at 2-4 weeks: recheck creatinine and potassium (watch for hyperkalemia or acute rise in creatinine >30%) 2
• Achieve target BP <130/80 mmHg within 3 months 1, 11, 12

Common Pitfalls to Avoid

1. Cough: The most common side effect (18.8-23.6% incidence, higher in women) 7. If intolerable, switch to an ARB rather than discontinuing RAAS blockade entirely 3

2. First-dose hypotension: Rare with benazepril monotherapy in uncomplicated hypertension, but counsel patients about dizziness 2, 9

3. Hyperkalemia: Monitor potassium, especially if patient later requires addition of potassium-sparing diuretics or has unrecognized renal dysfunction 2

4. Pregnancy: Absolutely contraindicated—counsel women of childbearing potential 2

If monotherapy is insufficient after 4 weeks at maximum dose, the 2024 ESC guidelines recommend adding either a dihydropyridine calcium channel blocker (preferred based on ACCOMPLISH trial data) or a thiazide diuretic 1, 4.